Answers are grounded in this paper and cite their sources.
Many advanced tumors produce excess amounts of Transforming Growth Factor-β (TGF-β), which is a potent growth inhibitor of normal epithelial cells. However, in tumors its homeostatic action on cells can be diverted along several alternative pathways. Thus, TGF-β signaling has been reported to elicit a preventative or tumor suppressive effect during the earlier stages of tumorigenesis, but later in tumor development, when carcinoma cells become refractory to TGF-β-mediated growth inhibition, response to TGF-β signaling elicits predominantly tumor progressing effects. This is not a simple switch from suppression to progression, but more like a rheostat, involving multiple complementary and antagonizing activities that slowly tip the balance from one to the other. This review will focus on the multiple activities of TGF-β in regulation of two epithelial tumor types, namely squamous cell carcinoma and breast cancer. Basic findings in current mouse models of cancer are presented, as well as a discussion of the complicating issue of outcome of altered TGFβ signaling depending on genetic variability between mouse strains. This review also discusses the role TGF-β within the tumor microenvironment particularly its ability to polarize the microenvironment towards a pro-tumorigenic milieu. Keywords: TGF-β, tumor microenvironment, breast cancer, epithelial cells, pro-tumorigenic milieu, squamous cell carcinoma, epithelial, hematopoietic, immune cells, malignant carcinoma, epithelial to mesenchymal transformation (EMT), multi-stage tumorigenesis model, lymph nodes and lungs, immature state, bone metastasis
No takes yet. Share an insight, caveat, or question.
Connolly et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: